In continuation of our earlier intimation dated December 16, 2025, and subsequent deferment notice dated December 22, 2025, we wish to inform you that the meeting of the Board of Directors ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Directors of Dr Lalchandani Labs Limited, at its meeting held on January 20, 2026, approved a Rights Issue of 43,32,000 fully paid-up equity shares of face value ₹10 each, aggregating up to ₹4.33 crore (assuming full subscription). The issue price is set at ₹10 per share (equal to face value, no premium), with a rights entitlement ratio of 1:1, meaning eligible shareholders can subscribe to one rights share for every one share held. The Record Date has been fixed as January 27, 2026, the issue opens on February 4, 2026, and closes on February 20, 2026. If fully subscribed, the company's outstanding equity shares will double from 43,33,068 to 86,65,068.
The 1:1 rights issue at face value could lead to a 100% increase in share count if fully subscribed, diluting existing shareholders who choose not to participate. Eligible shareholders need to act by the issue closing date of February 20, 2026, to avoid dilution of their stake.